XBiotech (XBIT) Enterprise Value (2015 - 2026)

XBiotech has reported Enterprise Value for 12 years, with the latest figure at -$39.4 million in Q2 2026.

• On a quarterly basis, Enterprise Value rose 36.84% year-over-year to -$39.4 million in Q2 2026; TTM through Jun 2026 was -$39.4 million, a 36.84% increase from a year earlier, with the FY2025 full-year figure at -$52.7 million, down 0.83% from the prior year.
• Enterprise Value was -$39.4 million for Q2 2026 at XBiotech, up from -$52.7 million in the prior quarter.
• The five-year high for Enterprise Value was $52.5 million in Q3 2024, with the low at -$110.6 million in Q4 2022.
• Average Enterprise Value over 5 years is -$46.7 million, with a median of -$54.4 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2024: Enterprise Value sank 445.36% in 2023, then soared 168.34% in 2024.
• Over 5 years, Enterprise Value stood at -$110.6 million in 2022, then increased by 29.25% to -$78.3 million in 2023, then soared by 33.25% to -$52.3 million in 2024, then dropped by 0.83% to -$52.7 million in 2025, then gained by 25.2% to -$39.4 million in 2026.
• The last three Enterprise Value figures came in at -$39.4 million (Q2 2026), -$52.7 million (Q4 2025), and -$66.3 million (Q3 2025), per Business Quant data.